ClinicalTrials.gg
CompletedNCT05031871Updated Oct 13, 2022

Pharmacokinetics of HR17031 Injection in Healthy Subjects

A Phase 1 interventional study of HR17031 injection ;INS068 injection;SHR20004 injection and HR17031 injection ;INS068 injection;SHR20004 injection in Type 2 Diabetes Mellitus, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
58th of 81
24 · median 80
Started
2021
with 7 others
Phase 1
48 of 81
4 open now
Registered
34th of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 58th largest by enrollment, is one of 8 that started in 2021, is one of 48 in phase 1, and was the 34th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

To compare the pharmacokinetics and safety of HR17031 injection, SHR20004 injection and/or INS068 injection in healthy subjects

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ranges from 18 to 27 kg/m2 (both ends included), and the body weight is ≥50 kg for men and ≥45 kg for women;
  2. Fasting blood glucose during the screening is \< 6.1 mmol/L;

Exclusion criteria

Exclusion Criteria:

  1. It has clinical significance for abnormalities Laboratory examination, if there is a clear reasonable reason, can be retested within a week, with the retest results Whether the subject meets the requirements
  2. Severe systemic disease, or a prior history of pancreatitis or other systemic problems within 1 month prior to screening;
  3. Participate in any clinical trial of a drug or medical device within 3 months prior to screening (subject to signed )
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment group A

    HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose

    Drug: HR17031 injection ;INS068 injection;SHR20004 injection

  • Experimental
    Treatment group B

    INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose

    Drug: HR17031 injection ;INS068 injection;SHR20004 injection

  • Experimental
    Treatment group C

    SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose

    Drug: HR17031 injection ;INS068 injection;SHR20004 injection

  • Experimental
    Treatment group D

    (INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose

    Drug: HR17031 injection ;INS068 injection;SHR20004 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax:Maximum observed concentration

    Time frame: Day1 to Day 26

  2. AUC0-t :Area under the curve from the time of dosing time to the last measurable (positive) concentration;

    Time frame: Day1 to Day 26

  3. AUC0-inf:Area under the curve from time 0 to infinity;

    Time frame: Day1 to Day 26

Secondary outcomes

  1. Tmax :time of maximum observed concentration

    Time frame: Day1 to Day 26

  2. T1/2:Half-life time ;

    Time frame: Day1 to Day 26

  3. CL/F

    Time frame: Day1 to Day 26

  4. Vz/F

    Time frame: Day1 to Day 26

  5. Serum glucose within 24h after injection

    Time frame: Day1 to Day 23

  6. C-peptide concentrations within 24h after injection

    Time frame: Day1 to Day 23

  7. ADA:anti-drug antibody

    Time frame: Day 1、Day 8、Day15、Day 22 or early termination

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Nov 2021, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2021
First posted
Sep 2, 2021
StartActual
Sep 2, 2021
Primary completionActual
Nov 19, 2021
CompletionActual
Nov 19, 2021
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05031871
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Sep 2, 2021
Primary completion
Nov 19, 2021
Completion
Nov 19, 2021
Last update
Oct 13, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR17031

Start the discussion